Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Metastatic NUT Carcinoma × 1,2-diaminocyclohexaneplatinum II citrate × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 3 Lung Neoplasms 2 Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Mouth Neoplasms 1 Metastatic NUT Carcinoma 1 Laryngeal Neoplasms 1 Infiltrating Bladder Urothelial Carcinoma 1 Hypopharyngeal Neoplasms 1 HIV Infections 1 Cholangiocarcinoma 1 Carcinoma 1

Interventions

molibresib 1 etoposide phosphate 1 Platinum 1 Etoposide 1 Cisplatin 1 1,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04116359 2020-09-28

Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma

National Cancer Institute (NCI)

Phase 1/2 Withdrawn

Metastatic NUT Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡